Castle Biosciences CSTL Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| NET REVENUES by Product | ||||||
| Dermatologic | $194.51M-10.1% | $216.37M-6.6% | $231.56M-6.7% | $248.09M-4.8% | $260.62M+1.4% | |
| Non-Dermatologic | $145.41M+13.7% | $127.86M+14.2% | $111.98M+14.1% | $98.18M+13.6% | $86.46M+15.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Castle Biosciences break its business down?
- Castle Biosciences (CSTL) reports net revenues by product across 2 parts — Dermatologic and Non-Dermatologic. Each is extracted from the segment footnotes and tracked over time.
- Where does Castle Biosciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Castle Biosciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
